Viewing nowCombinationPimavan ES Tablet 30/2.5 mg (Pimasartan, Amlodipine)
S-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 202204663 · Approved 2022.12.27 · Insurance code 657807830
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled with Pimasartan alone. It serves as an additional treatment option for cases where single-drug therapy is insufficient for blood pressure control. This helps to manage blood pressure more effectively and reduce the risk of complications due to hypertension.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the tablet be taken at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using fimasartan; however, if blood pressure is not controlled as described below, a direct switch to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. Elderly patients No initial dosage adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy in pediatric and adolescent patients aged 18 years or younger have not been established.
This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to any of the ingredients in this medication, those who are pregnant or breastfeeding, patients undergoing renal dialysis, patients with moderate to severe liver function impairment, individuals with biliary obstruction, specific diabetes patients, and those with genetic conditions such as lactose intolerance should not take this medication. Patients with low blood volume or salt deficiency may experience hypotension when starting this medication or increasing the dose, so their condition should be closely monitored. Caution is also required for patients with impaired kidney function or renovascular hypertension. This medication can cause side effects such as dizziness, headache, facial or peripheral edema, urinary disorders, insomnia, and flushing. Rarely, serious kidney issues, hypotension, liver function anomalies, and other complications have been reported. If symptoms of hypotension occur during treatment, immediate measures, such as lying the patient down and administering fluids if necessary, are required. Regular blood tests are recommended due to the risk of elevated potassium levels. This medication may interact with other antihypertensives, diuretics, potassium-sparing diuretics, certain antibiotics, lithium, grapefruit juice, etc., so it is essential to discuss any medications being taken with a physician or pharmacist. Women who are pregnant or breastfeeding should avoid taking this medication and should consult a healthcare professional if pregnancy is confirmed. Safety and efficacy for children and adolescents under 18 years old have not been established, thus its use is not recommended. Elderly patients may respond more sensitively to this medication, thus caution is advised during use. Patients with moderate to severe liver impairment should not take this medication. In cases of overdose, severe hypotension, palpitations, and bradycardia may occur, and immediate medical attention should be sought if these symptoms arise. This medication should be kept out of reach of children, and transferring it to another container may cause quality deterioration or accidents, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a special container that blocks light. Additionally, to maintain the efficacy of the medication, it should be stored at a temperature between 1 to 30 degrees Celsius.
White, round, film-coated tablet with a square shape
Bottle packaging - 30 tablets/bottle, Bottle packaging - 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication · Combination
Allico Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication · Combination
Allyco Pharmaceutical Co., Ltd.
S-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication · Combination
Shinpoong Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication · Combination
Shinpoong Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication · Combination
Hana Pharm Co., Ltd.
CombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 33.005mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Besylate Dihydrate 3.69mg · Fimasartan Potassium Trihydrate 66.01mg
Tablet · Prescription medication · Combination
Korea Hutech Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.